An In Vivo shRNA-Drug Screen to Identify Novel Targeted Therapy Combinations for KRAS Mutant Cancers
Annual rept. 1 September 2012 to 31 August 2013
MASSACHUSETTS GENERAL HOSPITAL BOSTON
Pagination or Media Count:
The primary shRNA-drug screen utilizing PDAC cell lines has been completed. The top 100 gene targets that specifically cooperate with MEK inhibitors were prioritized using the statistical RNAi gene enrichment ranking RIGER algorithm, which considers all shRNAs against a specific gene as a hairpin set . Construction of the inducible shRNA mini-pool based on the top 100 gene hits from the primary screen is currently underway. Upon completion, this shRNA mini-pool will be utilized to perform the secondary shRNA-drug screen in an orthotopic mouse pancreatic cancer model as originally proposed.
- Genetic Engineering and Molecular Biology